<DOC>
	<DOCNO>NCT02669277</DOCNO>
	<brief_summary>To demonstrate efficacy new product IVIG prepared minipool technology assess Bleeding Score platelet count 3 day , 1 week , 2 week 4 week . The platelet response rate define percentage subject respond treatment increase platelet count ≤ 20 x 10^9/L ≥ 100 x 10^9/L absence bleeding ( complete response ) platelet count ≥ 50 x 10^9/L least 2-fold increase base line count absence bleeding ( partial response ) , within specify time frame .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Single Dose Low Cost Minipool Intravenous Immunoglobulins Moderately Severe Newly Diagnosed ITP</brief_title>
	<detailed_description>To demonstrate efficacy new product IVIG prepared minipool technology assess Bleeding Score platelet count 3 day , 1 week , 2 week 4 week . The platelet response rate define percentage subject respond treatment increase platelet count ≤ 20 x 10^9/L ≥ 100 x 10^9/L absence bleeding ( complete response ) platelet count ≥ 50 x 10^9/L least 2-fold increase base line count absence bleeding ( partial response ) , within specify time frame . Secondary : 1 . To assess safety mini-pool IVIG patient newly diagnose ITP assess frequency adverse event related mini-pool IgG administration 2 . To compare data efficacy safety mini-pool IVIG data obtain literature standard IVIG . Study population : Patients newly diagnose ITP attend Hematology clinic Ain Shams Children hospital Sample size : Seventy- two patient enrol . They divide 3 group : Group A ; platelet non enhance group Group B ; group receive standard IVIG Group C ; group receive IVIG New product 24 patient group ratio 1:1:1 .</detailed_description>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . All newly diagnose ITP patient ( &lt; 2 week onset disease ) , platelet enhance therapy . 2 . Age eligible study : 116 year old 3 . Gender eligible study : sex 4 . Informed consent sign patient legal guardian . 1 . Patients start steroid therapy . 2 . Platelet count &lt; 10,000/mm3 . 3 . Having life threaten bleeding . 4 . Patients know suspected hypersensitivity immunoglobulins previous severe side effect immunoglobulin therapy . 5 . Treatment immunosuppressive immunomodulatory drug within 3 week prior screen . 6 . Treatment investigational drug within 7 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>